FDA grants priority review for PharmaMar’s Yondelis NDA
The drug is indicated to treat patients with STS, including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. STS are a type of cancer
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.
The cell bank contains over 2.6 billion human cells, sufficient to meet the company’s foreseeable clinical trial requirements. "Completing the production of clinical-grade cells using the previously published
Following a meeting with its CBD Initiative Scientific/Medical Advisory Board last November, the company has marked significant progress in readying its first natural CBD-based nutraceutical supplement for introduction
The drug is approved in combination with letrozole, to treat postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based